Introduction
============

Epithelial ovarian carcinoma (EOC) is a predominant, lethal gynecologic malignancy, with a five-year survival rate of \<25% for patients that are diagnosed with stage III--IV disease ([@b1-ol-07-04-1088],[@b2-ol-07-04-1088]). The treatment for EOC remains challenging, regardless of advances in surgical procedures and chemotherapy. The current ovarian cancer classification scheme distinguishes tumors based on the histopathological subtype, grade and surgical stage. Although established differences are observed in the clinical behavior, all of the ovarian neoplasia are subject to the same treatment paradigm. Therefore, the development of predictive markers that will direct the treatment selection, in addition to novel targeted therapies, are required for the treatment of EOC.

Aberrant DNA methylation is currently recognized as a common molecular abnormality in cancer. The abnormal promoter methylation may be a potential molecular marker for cancer diagnosis, prognosis and treatment ([@b3-ol-07-04-1088]--[@b5-ol-07-04-1088]). Recent studies have focused on the identification of methylated genes and the evaluation of their potential application as biomarkers for the prognosis and diagnosis of EOC ([@b6-ol-07-04-1088],[@b7-ol-07-04-1088]). However, it is particularly unclear which genes should be used to identify a methylator phenotype that may become instrumental in the clinical diagnosis, prognosis and treatment of cancer.

The breast cancer susceptibility gene 1 (*BRCA1*) is a significant breast and ovarian cancer susceptibility gene; it has been mapped to chromosome 17q21 and encodes a nuclear protein, which is comprised of 1863 amino acids ([@b8-ol-07-04-1088]). *BRCA1* contributes to the regulation of transcriptional activation, DNA repair, apoptosis, cell-cycle checkpoint control and chromosomal remodeling ([@b9-ol-07-04-1088],[@b10-ol-07-04-1088]). BRCA1 dysfunction, frequently observed in high-grade serous ovarian carcinomas, commonly results from germline and somatic mutations, as well as promoter methylation. Therefore, the identification of tumors exhibiting BRCA1 defects has therapeutic and prognostic implications ([@b11-ol-07-04-1088]--[@b16-ol-07-04-1088]). The hypermethylation of the *BRCA1* promoter is important in silencing *BRCA1* in sporadic EOCs, and previous studies have demonstrated that methylation of *BRCA1* is associated with chemotherapy sensitivity and patient survival ([@b17-ol-07-04-1088]--[@b20-ol-07-04-1088]). *BRCA1* CpG island hypermethylation predits sensitivity to poly (ADP-ribose) polymerase-1 inhibitors ([@b21-ol-07-04-1088]), thus indicating a potential role for *BRCA1* methylation as a biological marker in the clinical treatment of EOC.

DNA methyltransferases (DNMTs) are a family of enzymes responsible for the transfer of methyl groups to cytosine ([@b22-ol-07-04-1088],[@b23-ol-07-04-1088]) and the DNMT family includes DNMT1, 2, 3a, 3b and 3L ([@b24-ol-07-04-1088],[@b25-ol-07-04-1088]). DNMT2 (whose substrate and DNA methylation activity is unclear) ([@b26-ol-07-04-1088]), was shown to methylate transfer RNA ([@b27-ol-07-04-1088],[@b28-ol-07-04-1088]) and DNMT3L (which is essential for establishing maternal genomic imprints, however, lacks key methyltransferase motifs) is potentially a regulator of methylation rather than an enzyme that methylates DNA ([@b29-ol-07-04-1088]). It has been suggested that that global genomic DNA methylation patterns are established and predominantly maintained by the combined action of three enzymatically active DNMTs, 1, 3a and 3b. DNMT1 is traditionally referred to as a maintenance enzyme as it copies methylation following replication, whereas DNMT3a and DNMT3b are *de novo* enzymes, which establish novel patterns of methylation during differentiation ([@b30-ol-07-04-1088],[@b31-ol-07-04-1088]). Aberrant expression of DNMTs and disruption of DNA methylation patterns are closely associated with numerous types of cancer. Our previous study demonstrated that DNMT3a expression was higher in EOC ([@b32-ol-07-04-1088]), indicating an important role for the differential expression of DNMTs in aberrant DNA methylation patterns of EOC. However, there is currently no data concerning the association between DNMT expression and DNA methylation in EOC.

In the present study, the expression and methylation of *BRCA1* was investigated in the same cohort of ovarian tumor patients as our previous study ([@b32-ol-07-04-1088]) and the association between BRCA1 expression and methylation was analyzed. The clinicopathological and prognostic differences, based on *BRCA1* promoter methylation in EOC patients, were analyzed to determine the role of *BRCA1* methylation in EOC and to understand the clinical significance. Furthermore, the association between *BRCA1* methylation and DNMT protein expression was analyzed to investigate the role of DNMTs in *BRCA1* methylation.

Patients and methods
====================

Patients and tissue samples
---------------------------

The present study included 142 EOC cases and 32 ovarian benign tumor cases, which were selected from the Department of Surgical Oncology and General Surgery at the China Medical University-Affiliated First and Second Hospitals (Liaoning, China). All of the cases included in the present study were clinical cases that were routinely examined and diagnosed between 2002 and 2010. None of the patients had a family history of cancer and they were surgically staged according to the current International Federation of Gynecologists and Obstetricians (FIGO) classification system. The histological diagnosis was determined based on criteria set out by the World Health Organization ([@b33-ol-07-04-1088]). Approval for the present study was obtained from the Institute Research Medical Ethics Committee of the China Medical University (Liaoning, China). Consent was obtained from the families of all patients.

Immunohistochemical analysis
----------------------------

Formalin-fixed and paraffin-embedded tissue samples were cut into 4-μm sections and mounted onto poly-L-lysine-coated glass slides. For immunohistochemical staining, the sections were deparaffinized in xylene, rehydrated in a series of alcohol and washed using tap water. The sections were autoclaved in 10 mM sodium citrate buffer (pH 6.0; China National Pharmaceutical Group Corporation, Beijing, China) for 10 min for antigen retrieval. Endogenous peroxidase activity was blocked by incubating the sections in 3% H~2~O~2~ (China National Pharmaceutical Group Corporation) at 37°C for 20 min. The sections were blocked for non-specific binding by 10% normal goat serum at 37°C for 30 min and were incubated at 4°C overnight with mouse monoclonal anti-*BRCA1* antibodies (1:100; MS110, Calbiochem, Darmstadt, Germany). The following day, the sections were washed three times with 0.01 mol/l phosphate-buffered saline (PBS; pH 7.4) for 15 min and incubated with a goat anti-mouse IgG secondary antibody (catalogue no. sc-2039; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 30 min at 37°C. Subsequently, the sections were incubated with a streptavidin horseradish peroxidase solution (LSAB^TM^ kit, Dako, Glostrup, Denmark) for 30 min, washed with PBS and stained with 3,3′-diaminobenzidine. The sections were then counterstained with Mayer's hematoxylin (Sigma-Aldrich, St. Louis, MO, USA), dehydrated and mounted. The negative controls were generated using PBS as a replacement for the anti-BRCA1 antibodies.

Evaluation of immunohistochemistry
----------------------------------

The immunostained sections were independently reviewed and scored by two investigators who were blinded to the clinicopathological characteristics of the patients; a positive correlation was observed between them. The nuclear positivity of the BRCA1 proteins was evaluated using semi-quantitative scoring criteria according to the staining intensity (0, negative; 1, weak; 2, moderate; and 3, strong) and the proportion of positive cells (0, negative; 1, positive in ≤10%; 2, positive in \>10% and ≤50%; 3, positive in \>50% and ≤80%; 4, positive in \>80% of tumor cells). The two scores were multiplied together for each case and the expression was graded as: 0, negative score; 1--4, weak expression score; 5--8, moderate expression score; and 9--12, strong expression score.

Methylation-specific polymerase chain reaction (MSP)
----------------------------------------------------

The promoter methylation status of the *BRCA1* gene was analyzed using MSP. The bisulfite modification, primer sequences and PCR conditions were performed as previously described ([@b29-ol-07-04-1088]). Lymphocyte DNA, which was treated with *Sss*I bacterial methylase (New England BioLabs, Hithcin, UK) served as the positive control for the methylated alleles and the DNA from normal lymphocytes served as the control for the unmethylated alleles; the negative controls, without DNA, were included in each experiment. All PCR reactions were conducted in duplicate and a methylated band, which was detected in either or both duplicates, was recorded as positive for promoter methylation.

Statistical analysis
--------------------

Pairwise correlations between the categorical variables were investigated using the χ^2^ test or Fisher's exact test where appropriate. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and the log-rank test was used to compare the patient survival time between or among the groups. The Cox proportional hazards model (Cox regression) was used with backward elimination to identify the significant, independent, prognostic factors. OS was defined as the time interval from initial surgery to mortality or, for surviving patients, the time interval between the initial surgery and the final follow-up. DFS was defined as the time interval between the initial surgery and the date of disease progression or recurrence, or the final follow-up. The statistical tests were two-sided and P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using the SPSS statistical software program (SPSS, Chicago, IL, USA).

Results
=======

Patient characteristics
-----------------------

In the present study, the tissue sections were obtained from 174 ovarian tumor samples for the evaluation of BRCA1 protein expression and promoter methylation. The clinicopathological data from the patients are shown in [Table I](#tI-ol-07-04-1088){ref-type="table"}. Briefly, the mean age of the patients at the time of surgery was 53 years (range, 20--74 years). Twenty-seven (23.3%) patients exhibited lymph node-metastasized disease at the time of surgery and 110 (80.9%) patients exhibited serous carcinoma as the predominant histological diagnosis, followed by mucinous carcinoma (8.5%), clear cell carcinoma (5.6%) and undifferentiated carcinoma (5.6%). The preoperative serum levels of carbohydrate antigen (CA)-125 and CA19-9 were elevated prior to surgery (higher than in the levels of healthy individuals) in the majority of patients but none of the patients received any neo-adjuvant chemotherapy. Follow-up data were available for 85 patients. The mean and median OS times were 56.1 and 41.0 months with 95% confidence intervals (CIs) of 45.3--66.9 and 33.2--48.8 months, respectively. The mean and median DFS times were 46.6 and 26.0 months with 95% CIs of 36.4--56.9 and 14.6--37.4 months, respectively. The 32 benign tumors comprised of 27 that were serous and five that were mucinous.

BRCA1 promoter methylation is associated with low BRCA1 expression in EOC
-------------------------------------------------------------------------

The methylation of *BRCA1* was detected in 142 cases of malignant tumors and 32 cases of benign, ovarian tumors. *BRCA1* methylation was detected in 50 (35.2%) of the 142 carcinomas, however, no methylation was detected in the benign tumors. The frequency of *BRCA1* methylation was significantly higher in the EOC samples than that observed in the benign tumor samples (P\<0.001, Pearson's χ^2^ test).

The BRCA1 expression in the 142 carcinoma samples was as follows, 67 (47.2%) were negative and 62 (43.7%) were weakly positive, nine (6.3%) were moderately positive and four (2.8%) were strongly positive for BRCA1. Among the 32 cases of benign tumors; nine (28.1%) were negative and 15 (46.9%) were weakly positive, four (12.5%) were moderately positive and four (12.5%) were strongly positive for nuclear BRCA1. The expression of BRCA1 in the carcinoma samples was significantly reduced compared with that observed in the benign tumors (P=0.031, Pearson's χ^2^ test).

In the EOC samples, a reduction of the BRCA1 protein was significantly associated with *BRCA1* methylation (P\<0.001, Pearson's χ^2^ test; [Table II](#tII-ol-07-04-1088){ref-type="table"}). Representative results of the immunohistochemical staining and *BRCA1* promoter methylation in EOC tissues are shown in [Fig. 1](#f1-ol-07-04-1088){ref-type="fig"}.

BRCA1 promoter methylation is associated with clinicopathological parameters in EOC
-----------------------------------------------------------------------------------

The association between *BRCA1* promoter methylation and clinicopathological parameters is shown in [Table III](#tIII-ol-07-04-1088){ref-type="table"}. The data indicated that *BRCA1* methylation was significantly associated with tumor localization. In addition, the frequency of *BRCA1* methylation was observed to be higher in the patients whose tumor was bilateral than that of patients whose tumor unilateral (P=0.015, Pearson's χ^2^ test). Moreover, the methylation of the *BRCA1* gene was marginally associated with the FIGO clinical stage (P=0.085, Pearson's χ^2^ test).

CA-125, CA19-9 and carcinoembryonic antigen (CEA) are the predominant biomarkers for confirming the diagnosis and management of EOC. Although they commonly aid with the diagnosis of ovarian malignancies, there are significant limitations relating to their sensitivity and specificity. The association between *BRCA1* gene promoter methylation and preoperative serum levels of CA-125, CA19-9 and CEA were analyzed in the present study and *BRCA1* methylation was observed to be significantly associated with the CA-125 level. The frequency of *BRCA1* methylation was greater in patients exhibiting higher preoperative CA-125 levels than that observed in patients exhibiting lower CA-125 levels (P=0.013, Pearson's χ^2^ test).

BRCA1 promoter methylation is associated with an improved survival rate
-----------------------------------------------------------------------

In the present study *BRCA1* methylation did not correlate with the patient survival rate in all of the patients (OS: P=0.932; [Fig. 2A](#f2-ol-07-04-1088){ref-type="fig"} and DFS: P=0.794; [Fig. 2B](#f2-ol-07-04-1088){ref-type="fig"}). However, in the patients exhibiting advanced stage (III--IV) cancer, *BRCA1* methylation was significantly associated with improved OS (P=0.005; [Fig. 2C](#f2-ol-07-04-1088){ref-type="fig"}) and DFS (P=0.007; [Fig. 2D](#f2-ol-07-04-1088){ref-type="fig"}).

Cox regression univariate analysis of the potential prognostic impact of the clinical and histopathological parameters enabled identification of the FIGO clinical stage (OS: P=0.003; RR=8.750; 95% CI, 2.072--36.951; and DFS: P=0.001; RR=7.446; 95% CI, 2.279--24.331), the location of the tumor (OS: P=0.075; RR=2.019; 95% CI, 0.931--4.376; and DFS: P=0.024; RR=2.227; 95% CI, 1.112--4.462) and the serum CA-125 level (OS: P=0.113; RR=1.688; 95% CI, 0.884--3.224; and DFS, P=0.007; RR=2.067; 95% CI, 1.218--3.508) are significantly associated with a reduced OS and DFS ([Table IV](#tIV-ol-07-04-1088){ref-type="table"}). Subsequently, multivariate Cox regression models using the clinical stage, tumor size, location of neoplasia and *BRCA1* methylation revealed that the clinical stage alone provided the independent prognostic factor (OS: P=0.012; RR=7.315; 95% CI, 1.552--34.481; and DFS: P=0.008; RR=5.535; 95% CI, 1.552--19.739) ([Table V](#tV-ol-07-04-1088){ref-type="table"}).

DNMT co-expression is associated with BRCA1 methylation in EOC
--------------------------------------------------------------

In the present study the correlation between DNMT expression and *BRCA1* methylation was analyzed ([Table VI](#tVI-ol-07-04-1088){ref-type="table"}). No significant correlation between the methylation status of *BRCA1* and DNMT1, 3a, or 3b protein expression was observed (P=0.135, P=0.824 and P=0.260, respectively). However, a significant correlation was observed between the methylation status of *BRCA1* and the co-expression of any two of the DNMTs or all three of the DNMTs. The methylation rates of *BRCA1* in the samples exhibiting co-expression of DNMT1 and 3a, DNMT1 and 3b, or DNMT3a and 3b, were greater than the rates observed in the non-co-expression samples (P=0.030, P=0.034 and P=0.046, respectively). Additionally, when all three of the DNMTs were positive, the highest *BRCA1* methylation rate was observed (59.0%).

Discussion
==========

The loss of expression of tumor suppressor genes is known to occur via biallelic inactivation ([@b35-ol-07-04-1088]). The current consensus is that the somatic mutation of *BRCA1* is rare in sporadic EOC, thus, the loss of BRCA1 expression is considered to be due to a combination of allelic loss and methylation or biallelic methylation ([@b36-ol-07-04-1088],[@b37-ol-07-04-1088]). Promoter methylation is significant in silencing *BRCA1*. The varying experimental methods and, in particular, the region of the *BRCA1* promoter that has been investigated across studies have identified a range of frequencies of *BRCA1* promoter methylation, from 5 to 40% of clinical specimens ([@b38-ol-07-04-1088]). In the present study, the methylation rate of *BRCA1* in EOC samples is consistent with that observed in previous studies and *BRCA1* promoter methylation was significantly associated with a decreased expression of *BRCA1*. These results corroborated the hypothesis that *BRCA1* hypermethylation was a predominant cause of BRCA1 loss of expression.

Previous studies regarding the association between *BRCA1* gene promoter methylation and patient survival remain controversial. Montavon *et al* ([@b6-ol-07-04-1088]) and Yang *et al* ([@b39-ol-07-04-1088]) indicated that *BRCA1* methylation was not associated with patient survival, however, another study demonstrated a survival disadvantage in patients whose neoplasms were methylated at *BRCA1* ([@b17-ol-07-04-1088]). In the present study, a significant association was observed between *BRCA1* methylation and an improved survival rate in patients with an advanced FIGO stage (III--IV). The inconsistency of these results may be due to the varying regions of the *BRCA1* promoter that were investigated in addition to the different populations that were involved in the studies. The data from the present study resulted in the hypothesis that the cells from the patients with methylation of the *BRCA1* promoter may exhibit an impaired ability to repair DNA damage via downregulation of *BRCA1* expression. The patients may experience an increased sensitivity to platinum chemotherapy, resulting in an improved survival outcome. These results were consistent with previous studies, which demonstrated that *BRCA1* gene promoter methylation may be an effective indicator of the patient response to chemotherapy ([@b20-ol-07-04-1088],[@b21-ol-07-04-1088]). As there were limitations in the present study due to the small number of cases, further investigation is required to clarify the role of *BRCA1* gene methylation in chemoresponsiveness and patient survival in EOC cases.

The present study indicated that *BRCA1* methylation was significantly associated with the tumor location. Furthermore, the frequency of *BRCA1* methylation was observed to be greater in patients with bilateral ovarian cancer than in unilateral cancer patients, which may indicate a contrast between the unilateral and bilateral ovarian cancers regarding their biological characteristics, genetics and mechanisms of carcinogenesis. Moreover, these data indicated that *BRCA1* methylation was significantly associated with the preoperative serum CA-125 levels. CA-125 was established as a prognostic marker in cancer, specifically in ovarian carcinoma ([@b40-ol-07-04-1088]) and the present results indicated that *BRCA1* methylation and CA-125 levels, in combination, may be used as biomarkers for the diagnosis and prognosis of EOC.

The causes of DNA methylation at specific CpG islands in cancer are ambiguous and potentially multifactorial. DNMTs were a predominant cause of DNA methylation and the differential expression of DNMTs has been identified in numerous types of cancer ([@b41-ol-07-04-1088]--[@b43-ol-07-04-1088]), including EOC, which we previously reported ([@b32-ol-07-04-1088]). It was hypothesized in the present study that the over-expression of DNMT proteins may contribute to *BRCA1* methylation; therefore, the association between *BRCA1* methylation and DNMT protein expression was analyzed. The results indicated that there was no significant correlation identified between the methylation status of *BRCA1* and the individual protein expression of DNMT1, 3a or 3b. However, the co-expression of DNMTs was identified to be significantly associated with *BRCA1* methylation. The results of the present study supported the hypothesis that genomic methylation patterns may be established depending on the interaction of these three enzymes. Further studies are required to clarify how these DNMTs interact with each other.

In conclusion, *BRCA1* gene promoter methylation was identified to be significant in reducing protein expression in a Chinese population and the co-expression of DNMTs may have contributed to *BRCA1* gene promoter hypermethylation. Moreover, *BRCA1* gene promoter hypermethylation was observed to be significantly associated with a favorable survival rate, thus supporting the hypothesis that *BRCA1* methylation may be an important prognostic marker for EOC.
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![Immunohistochemical staining and methylation of *BRCA1* in sporadic EOC tissues. (A) Immunohistochemical staining of sporadic EOC specimens (magnification, ×1000): (a) Negative stain; (b) weak positive stain; (c) moderately positive stain; (d) strongly positive stain. (B) Methylation of *BRCA1*. MSP was performed on bisulfite-treated DNA from ovarian cancer cells. MSP results from nine representative patients are shown. The DNA bands in the u-labeled lanes indicate PCR products that were amplified with primers recognizing the unmethylated promoter sequence. The DNA bands in m-labeled lanes represent the products that were amplified with methylation-specific primers. The DNA from the normal lymphocytes served as the control for UMD and IVD served as the control for methylated DNA. H~2~O was used as a template for the negative control. M, marker; UMD, unmethylated DNA; IVD, *in vitro* methylated DNA; *BRCA1*, breast cancer susceptibility gene 1; EOC, epithelial ovarian carcinoma; MSP, methylation-specific polymerase chain reaction.](OL-07-04-1088-g00){#f1-ol-07-04-1088}

![Kaplan-Meier curves for OS and DFS according to the *BRCA1* methylation status. (A) *BRCA1* methylation and OS in all cases (P=0.932). (B) *BRCA1* methylation and DFS in all cases (P=0.794). (C) *BRCA1* methylation and OS in the subgroups of stage III--IV cases (P=0.005). (D) *BRCA1* methylation and DFS in the subgroups of stage III--IV cases (P=0.007). P-value obtained from log-rank test. OS, overall survival; DFS, disease-free survival; *BRCA1*, breast cancer susceptibility gene 1.](OL-07-04-1088-g01){#f2-ol-07-04-1088}

###### 

Patient characteristics.

  Characteristic      n     \%
  ------------------- ----- ------
  Age (years)               
   ≤53                79    57.2
   \>53               59    42.8
   Unknown            4     \-
  Menopause state           
   Pre-menopause      45    34.6
   Post-menopause     85    65.4
   Unknown            12    \-
  Histological type         
   Serous             110   77.5
   Mucinous           12    8.5
   Clear cell         8     5.6
   Transitional       2     1.4
   Endometrioid       2     1.4
   Undifferentiated   8     5.6
  Tumor size (cm)           
   ≤5                 15    12.5
   5--10              53    44.2
   \>10               51    43.3
   Unknown            23    \-
  FIGO stage                
   I--II              31    24.4
   III--IV            96    75.6
   Unknown            15    \-
  Node metastasis           
   No                 89    76.7
   Yes                27    23.3
   Unknown            26    \-
  Location of tumor         
   Single side        56    43.4
   Both sides         73    56.6
   Unknown            13    \-
  CA-125 (U/ml)             
   0--35              10    10.1
   35--500            40    40.4
   500--1000          32    32.3
   \>1000             17    17.2
   Unknown            43    \-
  CA19--9 (U/ml)            
   0--37              67    76.1
   37--100            10    11.4
   \>100              11    12.5
   Unknown            54    \-
  CEA (ng/ml)               
   0--5               72    91.1
   \>5                7     8.9
   Unknown            63    \-
  Chemotherapy              
   Platinum-based     111   94.9
   Non-platinum       3     2.6
   No chemotherapy    3     2.6
   Unknown            25    \-

Unknown: these features were unavailable from the clinical-pathological records of the patients. FIGO, International Federation of Gynecology and Obstetrics; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.

###### 

Correlation between *BRCA1* expression and *BRCA1* methylation in 142 sporadic EOC cases.

                    *BRCA1* methylation, n (%)               
  ----------- ----- ---------------------------- ----------- ---------
  Malignant   142   50 (35.2)                    92 (64.8)   \<0.001
   Negative   67    35 (52.2)                    32 (48.7)   
   Positive   75    15 (20.0)                    60 (80.0)   

*BRCA1*, breast cancer susceptibility gene 1; EOC, epithelial ovarian carcinoma.

###### 

Correlation between *BRCA1* promoter methylation and clinicopathological features of sporadic EOC patients.

                                   *BRCA1* methylation, n (%)               
  -------------------------- ----- ---------------------------- ----------- -------
  Age at diagnosis (years)   138                                            
   ≤53                       79    26 (32.9)                    53 (67.1)   0.742
   \>53                      59    21 (35.6)                    38 (64.4)   
  Menopause state            130                                            
   Pre-menopause             45    13 (28.9)                    32 (71.1)   0.318
   Post-menopause            85    32 (37.6)                    53 (62.4)   
  Tumor size (cm)            119                                            
   ≤5.0                      15    5 (33.3)                     10 (66.7)   0.282
   5--10                     53    15 (28.3)                    38 (71.7)   
   \>10                      51    22 (43.1)                    29 (56.9)   
  Node metastasis            116                                            
   No                        89    31 (34.8)                    58 (65.2)   0.834
   Yes                       27    10 (37.0)                    17 (63.0)   
  FIGO stage                 127                                            
   I--II                     31    7 (22.6)                     24 (77.4)   0.085
   III--IV                   96    38 (39.6)                    58 (60.4)   
  Histological type          130                                            
   Serous                    110   38 (34.5)                    72 (65.5)   0.506
   Mucinous                  12    2 (16.7)                     10 (83.3)   
   Clear cell                8     3 (37.5)                     5 (62.5)    
  Tumor location             129                                            
   Single side               56    11 (19.6)                    45 (80.4)   0.015
   Both sides                73    29 (39.7)                    44 (60.3)   
  CA-125 (U/ml)              89                                             
   35--500                   40    9 (22.5)                     31 (77.5)   0.013
   500--1000                 32    18 (56.2)                    14 (43.8)   
   \>1000                    17    7 (41.2)                     10 (58.8)   
  CA19-9 (U/ml)              88                                             
   0--37                     67    24 (35.8)                    43 (64.2)   0.083
   \>37                      21    12 (57.1)                    9 (42.9)    
  CEA (U/ml)                 79                                             
   0--5                      72    20 (27.8)                    52 (72.2)   0.191
   \>5                       7     4 (57.1)                     3 (42.9)    

Obtained from Pearson's χ^2^ or Fisher's exact test.

*BRCA1*, breast cancer susceptibility gene 1; EOC, epithelial ovarian carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.

###### 

Univariate Cox regression analysis of OS and DFS in EOC.

                                 OS      DFS                                             
  ------------------------- ---- ------- --------------- ------- ------- --------------- -------
  Age (years)                                                                            
   \>53/≤53                 85   1.283   0.638--2.583    0.485   1.330   0.724--2.442    0.357
  Menopause state                                                                        
   Post/pre-                83   1.187   0.532--2.649    0.676   1.335   0.668--2.667    0.413
  Tumor size (cm)                                                                        
   \>5/≤5                   70   1.599   0.371--6.889    0.529   1.759   0.418--7.399    0.441
  Node metastasis                                                                        
   Yes/no                   68   1.695   0.708--4.055    0.236   1.114   0.483--2.571    0.799
  Histological type                                                                      
   Serous/non-serous        84   0.950   0.411--2.197    0.904   0.886   0.423--1.853    0.748
  FIGO stage                                                                             
   III--IV/I--II            79   8.750   2.072--36.951   0.003   7.446   2.279--24.331   0.001
  Location of neoplasia                                                                  
   Bilateral/unilateral     78   2.019   0.931--4.376    0.075   2.227   1.112--4.462    0.024
  CA-125 (U/ml)                                                                          
   \>1000/500-1000/35-500   56   1.688   0.884--3.224    0.113   2.067   1.218--3.508    0.007
  CA19-9 (U/ml)                                                                          
   \>37/0--37               53   0.366   0.085--1.579    0.178   0.399   0.119--1.342    0.138

OS, overall survival; DFS, disease-free survival; EOC, epithelial ovarian cancer; RR, relative risk; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; CA, carbohydrate antigen.

###### 

Multivariate Cox regression analysis of OS and DFS in EOC.

                          OS                      DFS                             
  ----------------------- ----------------------- ------- ----------------------- -------
  Clinical stage                                                                  
   III--IV/I--II          7.315 (1.552--34.481)   0.012   5.535 (1.552--19.739)   0.008
  Tumor size (cm)                                                                 
   \>5/≤5                 2.383 (0.534--10.636)   0.255   2.435 (0.567--10.458)   0.231
  Location of neoplasia                                                           
   Bilateral/unilateral   1.210 (0.425--3.445)    0.721   1.429 (0.563--3.625)    0.453
  *BRCA1* methylation                                                             
   Positive/negative      0.448 (0.157--1.281)    0.134   0.584 (0.256--1.332)    0.201

OS, overall survival; DFS, disease free survival; EOC, epithelial ovarian carcinoma; RR, relative risk; CI, confidence interval; *BRCA1*, breast cancer susceptibility gene 1.

###### 

Correlation between DNMT expression and *BRCA1* methylation in 142 sporadic EOC cases.

                                     *BRCA1* methylation, n (%)               
  --------------------- ------------ ---------------------------- ----------- ---------
  DNMT3a status                                                               
   Negative             50 (35.2)    33 (66.0)                    17 (34.0)   0.824
   Positive             92 (64.8)    59 (64.1)                    33 (35.9)   
  DNMT3b status                                                               
   Negative             63 (44.4)    44 (69.8)                    19 (30.2)   0.260
   Positive             79 (55.6)    48 (60.8)                    31 (39.2)   
  DNMT1 status                                                                
   Negative             66 (46.5)    47 (71.2)                    19 (28.8)   0.135
   Positive             76 (53.5)    45 (59.2)                    31 (40.8)   
  DNMT1+DNMT3a                                                                
   No co-expression     88 (62.0)    63 (71.6)                    25 (28.4)   0.030
   Co-expression        54 (38.0)    29 (53.7)                    25 (46.3)   
  DNMT1+DNMT3b                                                                
   No co-expression     93 (65.5)    66 (71.0)                    27 (29.0)   0.034
   Co-expression        49 (34.5)    26 (53.1)                    23 (46.9)   
  DNMT3a+DNMT3b                                                               
   No co-expression     84 (59.2)    60 (71.4)                    24 (28.6)   0.046
   Co-expression        58 (40.8)    32 (55.2)                    26 (44.8)   
  DNMT1+DNMT3a+DNMT3b                                                         
   No co-expression     103 (72.5)   76 (73.8)                    27 (26.2)   \<0.001
   Co-expression        39 (27.5)    16 (41.0)                    23 (59.0)   

Obtained from Pearson's χ^2^ or Fisher's exact test.

DNMT, DNA methyltransferase; *BRCA1*, breast cancer susceptibility gene 1.
